fabrizio De Benedetti

List of Publications by Citations

246 papers	11,151 citations	57 h-index	100 g-index
307 ext. papers	13,384 ext. citations	5.7 avg, IF	6 L-index

#	Paper	IF	Citations
246	Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. *New England Journal of Medicine*, **2012**, 367, 2385-95	59.2	577
245	Interleukin 6 is required for the development of collagen-induced arthritis. *Journal of Experimental Medicine*, **1998**, 187, 461-8	16.6	495
244	On the Alert for Cytokine Storm: Immunopathology in COVID-19. *Arthritis and Rheumatology*, **2020**, 72, 1059-1063	9.5	394
243	Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. *Journal of Clinical Investigation*, **1997**, 99, 643-50	15.9	370
242	Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. *Arthritis and Rheumatism*, **1991**, 34, 1158-63		285
241	American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care and Research*, **2011**, 63, 929-36	4.7	277
240	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Annals of the Rheumatic Diseases*, **2016**, 75, 481-9	2.4	247
239	Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. *Arthritis and Rheumatism*, **2006**, 54, 3551-63		234
238	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis and Rheumatology*, **2016**, 68, 566-76	9.5	216
237	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. *New England Journal of Medicine*, **2018**, 378, 1908-1919	59.2	214
236	Macrophage activation syndrome in the era of biologic therapy. *Nature Reviews Rheumatology*, **2016**, 12, 259-68	8.1	209
235	Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2002**, 46, 2402-9		207
234	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Annals of the Rheumatic Diseases*, **2015**, 74, 1110-7	2.4	195
233	Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. *Journal of Clinical Investigation*, **1994**, 93, 2114-9	15.9	188
232	Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. *Rheumatology*, **2010**, 49, 441-9	3.9	169
231	Translating IL-6 biology into effective treatments. *Nature Reviews Rheumatology*, **2020**, 16, 335-345	8.1	164
230	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. *New England Journal of Medicine*, **2020**, 382, 1811-1822	59.2	161

229	Classification criteria for autoinflammatory recurrent fevers. *Annals of the Rheumatic Diseases*, **2019**, 78, 1025-1032	2.4	159
228	Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2003**, 48, 1398-407		156
227	Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *Annals of the Rheumatic Diseases*, **2017**, 76, 166-172	2.4	154
226	Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. *Arthritis and Rheumatology*, **2015**, 67, 3037-46	9.5	153
225	Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. *Blood*, **1996**, 87, 4824-4830	2.2	146
224	Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. *Endocrinology*, **2001**, 142, 4818-26	4.8	130
223	Cisternal CSF levels of cytokines after subarachnoid hemorrhage. *Neurological Research*, **1998**, 20, 337-42	2.7	124
222	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. *Journal of Pediatrics*, **1996**, 128, 275-8	3.6	124
221	An international registry on autoinflammatory diseases: the Eurofever experience. *Annals of the Rheumatic Diseases*, **2012**, 71, 1177-82	2.4	121
220	NGF and Its Receptors in the Regulation of Inflammatory Response. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	120
219	A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2004**, 50, 1604-10		115
218	Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 14384-14389	11.5	107
217	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. *Annals of the Rheumatic Diseases*, **2010**, 69 Suppl 1, i2-29	2.4	102
216	Abnormal production of tumor necrosis factor (TNF) -- alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. *Journal of Pediatrics*, **2004**, 145, 851-5	3.6	101
215	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. *Annals of the Rheumatic Diseases*, **2018**, 77, 819-828	2.4	99
214	Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. *Journal of Bone and Mineral Research*, **2011**, 26, 1891-903	6.3	99
213	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Annals of the Rheumatic Diseases*, **2013**, 72 Suppl 2, ii2-34	2.4	96
212	Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. *Pediatric Rheumatology*, **2017**, 15, 5	3.5	92

211	Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. *Arthritis and Rheumatism*, **2012**, 64, 1680-8		87
210	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Annals of the Rheumatic Diseases*, **2008**, 67 Suppl 3, iii2-25	2.4	81
209	Inflammatory Cytokine response in a cohort of patients carrying novel NLRP12 variants. *Pediatric Rheumatology*, **2015**, 13, O23	3.5	78
208	Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra. *Pediatric Rheumatology*, **2015**, 13,	3.5	78
207	A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis. *Pediatric Rheumatology*, **2014**, 12,	3.5	78
206	Clinical presentation and cytokine production abnormalities in a cohort of patients carrying NLRP12 gene variants. *Pediatric Rheumatology*, **2014**, 12, P71	3.5	78
205	Nerve growth factor downregulates inflammatory response in human monocytes through TrkA. *Journal of Immunology*, **2014**, 192, 3345-54	5.3	77
204	ELISA qualitative screening of chloramphenicol in muscle, eggs, honey and milk: method validation according to the Commission Decision 2002/657/EC criteria. *Analytica Chimica Acta*, **2005**, 535, 43-48	6.6	77
203	c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. *Nature Communications*, **2012**, 3, 630	17.4	76
202	Interleukin-1 and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. *Molecular Medicine*, **2010**, 16, 552-7	6.2	75
201	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. *Arthritis Care and Research*, **2018**, 70, 409-419	4.7	72
200	Performance of a component-based allergen-microarray in the diagnosis of cow milk and hen egg allergy. *Clinical and Experimental Allergy*, **2010**, 40, 1561-70	4.1	72
199	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. *Journal of Experimental Medicine*, **2019**, 216, 2778-2799	16.6	71
198	Neutralization of IFN- reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1439-1449	11.5	64
197	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. *Arthritis and Rheumatism*, **1999**, 42, 807-11		63
196	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Annals of the Rheumatic Diseases*, **2012**, 71 Suppl 2, i2-45	2.4	62
195	Emergent high fatality lung disease in systemic juvenile arthritis. *Annals of the Rheumatic Diseases*, **2019**, 78, 1722-1731	2.4	61
194	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2002**, 46, 232-7		60

193	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. *Annals of the Rheumatic Diseases*, **2011**, 70 Suppl 1, i2-36	2.4	58
192	A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. *Journal of Immunology*, **2016**, 196, 2492-503	5.3	58
191	Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 1163-9	12.7	57
190	Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. *Arthritis and Rheumatism*, **2002**, 46, 2721-9		57
189	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. *Frontiers in Pharmacology*, **2016**, 7, 380	5.6	57
188	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. *Clinical Infectious Diseases*, **2020**, 71, 2272-2275	11.6	55
187	Deregulation of the IL-1 axis in chronic recurrent multifocal osteomyelitis. *Pediatric Rheumatology*, **2014**, 12, 30	3.5	55
186	Development of the autoinflammatory disease damage index (ADDI). *Annals of the Rheumatic Diseases*, **2017**, 76, 821-830	2.4	54
185	Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 653-9	6.9	53
184	Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. *Arthritis and Rheumatology*, **2015**, 67, 840-8	9.5	52
183	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. *Clinical Rheumatology*, **2018**, 37, 2233-2240	3.9	52
182	Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. *Journal of Rheumatology*, **2013**, 40, 761-7	4.1	49
181	Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. *Journal of Pediatrics*, **1994**, 124, 561-5	3.6	49
180	Low serum levels of mannose binding lectin are a risk factor for neonatal sepsis. *Pediatric Research*, **2007**, 61, 325-8	3.2	48
179	Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade. *EBioMedicine*, **2015**, 2, 285-93	8.8	47
178	Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. *Arthritis and Rheumatism*, **2002**, 46, 3015-25		47
177	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *RMD Open*, **2016**, 2, e000161	5.9	46
176	Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. *Journal of Pediatric Gastroenterology and Nutrition*, **1995**, 20, 23-7	2.8	46

175	Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations. *Journal of Pediatrics*, **1994**, 124, 742-4	3.6	46
174	Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. *Italian Journal of Pediatrics*, **2018**, 44, 102	3.2	45
173	A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFN) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH. *Blood*, **2015**, 126, LBA-3-LBA-3	2.2	44
172	Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. *Journal of Clinical Immunology*, **2019**, 39, 476-485	5.7	43
171	In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. *Journal of Immunology*, **2001**, 166, 4334-40	5.3	43
170	Anakinra in children and adults with Still disease. *Rheumatology*, **2019**, 58, vi9-vi22	3.9	42
169	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. *Arthritis Research and Therapy*, **2018**, 20, 285	5.7	41
168	Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience. *Journal of Rheumatology*, **2015**, 42, 1523-7	4.1	39
167	Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice. *Human Molecular Genetics*, **2015**, 24, 6041-53	5.6	39
166	IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. *PLoS ONE*, **2014**, 9, e107886	3.7	39
165	Symptom onset-to-balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention. *Heart*, **2012**, 98, 1738-42	5.1	39
164	Effect of IL-6 on IGF Binding Protein-3: A Study in IL-6 Transgenic Mice and in Patients with Systemic Juvenile Idiopathic Arthritis		39
163	Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. *Archives of Disease in Childhood*, **1993**, 69, 232-5	2.2	36
162	Use of a mouse model to identify a blood biomarker for IFN activity in pediatric secondary hemophagocytic lymphohistiocytosis. *Translational Research*, **2017**, 180, 37-52.e2	11	35
161	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. *Lancet, The*, **2017**, 389, 909-916	40	34
160	Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation. *European Journal of Pediatrics*, **2014**, 173, 1391-4	4.1	34
159	Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy. *Neurology*, **2012**, 78, 1309-14	6.5	34
158	Cytokines in juvenile rheumatoid arthritis. *Current Opinion in Rheumatology*, **1997**, 9, 428-33	5.3	34

157	Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. *Best Practice and Research in Clinical Rheumatology*, **2017**, 31, 505-516	5.3	32
156	Association of serum interleukin-8 levels with the degree of fibrosis in infants with chronic liver disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2004**, 39, 540-4	2.8	32
155	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman disease. *American Journal of Hematology*, **1994**, 46, 189-93	7.1	32
154	Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. *Arthritis and Rheumatology*, **2019**, 71, 1011-1021	9.5	31
153	Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. *Italian Journal of Pediatrics*, **2018**, 44, 103	3.2	31
152	Role of mannose-binding lectin in nosocomial sepsis in critically ill neonates. *Human Immunology*, **2010**, 71, 1084-8	2.3	30
151	Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study. *Arthritis and Rheumatology*, **2019**, 71, 1000-1010	9.5	30
150	Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. *Journal of Rheumatology*, **2012**, 39, 1287-90	4.1	29
149	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. *Pediatric Rheumatology*, **2016**, 14, 68	3.5	28
148	Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. *Journal of Rheumatology*, **2004**, 31, 795-800	4.1	28
147	The mature/pro nerve growth factor ratio is decreased in the brain of diabetic rats: Analysis by ELISA methods. *Brain Research*, **2015**, 1624, 455-468	3.7	27
146	Role of interleukin-6 in growth failure: an animal model. *Hormone Research in Paediatrics*, **2002**, 58 Suppl 1, 24-7	3.3	27
145	Stimulating effect of growth hormone on cytokine release in children. *European Journal of Endocrinology*, **2003**, 149, 397-401	6.5	26
144	Tumor necrosis factor in plasma and peritoneal fluid of women with and without endometriosis. *Gynecologic and Obstetric Investigation*, **1993**, 36, 39-41	2.5	26
143	Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. *Rheumatology*, **1997**, 36, 581-8	3.9	25
142	Serum cytokine levels in GH-deficient children during substitutive GH therapy. *European Journal of Endocrinology*, **2005**, 152, 207-10	6.5	25
141	Inflammatory events during food protein-induced enterocolitis syndrome reactions. *Pediatric Allergy and Immunology*, **2017**, 28, 464-470	4.2	24
140	A polymorphism in the macrophage migration inhibitory factor promoter is associated with bronchopulmonary dysplasia. *Pediatric Research*, **2011**, 69, 142-7	3.2	24

139	Relapsing polychondritis: new therapeutic strategies with biological agents. *Rheumatology International*, **2010**, 30, 691-3	3.6	24
138	Targeting interleukin-6 in pediatric rheumatic diseases. *Current Opinion in Rheumatology*, **2009**, 21, 533-7	5.3	23
137	Association of the macrophage migration inhibitory factor -173*C allele with childhood nephrotic syndrome. *Pediatric Nephrology*, **2008**, 23, 743-8	3.2	22
136	The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. *Leukemia*, **2005**, 19, 2346-7	10.7	21
135	Anakinra in a Cohort of Children with Chronic Nonbacterial Osteomyelitis. *Journal of Rheumatology*, **2017**, 44, 1231-1238	4.1	20
134	Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA). *Pediatric Rheumatology*, **2014**, 12,	3.5	19
133	Association between mannose-binding lectin gene polymorphisms and necrotizing enterocolitis in preterm infants. *Journal of Pediatric Gastroenterology and Nutrition*, **2012**, 55, 160-5	2.8	19
132	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. *Annals of the Rheumatic Diseases*, **2020**, 79, 1362-1369	2.4	18
131	Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency. *Journal of Rheumatology*, **2019**, 46, 523-526	4.1	17
130	In silico validation of the Autoinflammatory Disease Damage Index. *Annals of the Rheumatic Diseases*, **2018**, 77, 1599-1605	2.4	17
129	The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. *Hormone Research*, **2009**, 72 Suppl 1, 26-9		17
128	Increased risk of invasive meningococcal disease, pregnancy, and confounding. *Pediatrics*, **2005**, 116, 798-9; author reply 799	7.4	16
127	Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors. *Arthritis and Rheumatology*, **2018**, 70, 606-615	9.5	15
126	Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. *European Journal of Paediatric Neurology*, **2012**, 16, 301-3	3.8	15
125	Increased Circulating Levels of Interleukin-6 Affect the Redox Balance in Skeletal Muscle. *Oxidative Medicine and Cellular Longevity*, **2019**, 2019, 3018584	6.7	15
124	Monocytes and macrophages as biomarkers for the diagnosis of megalencephalic leukoencephalopathy with subcortical cysts. *Molecular and Cellular Neurosciences*, **2013**, 56, 307-21	4.8	14
123	SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS **2011**, 236-248		14
122	Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients. *European Journal of Immunology*, **2021**, 51, 206-219	6.1	14

121	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. *Frontiers in Pharmacology*, **2019**, 10, 918	5.6	13
120	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). *Pediatric Rheumatology*, **2018**, 16, 27	3.5	13
119	Systemic Juvenile Idiopathic Arthritis **2016**, 205-216.e6		13
118	Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis. *Blood*, **2018**, 132, LBA-6-LBA-6	2.2	13
117	OP0204 EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) **2019**,		13
116	ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis. *RMD Open*, **2017**, 3, e000441	5.9	12
115	Renal involvement in hypocomplementaemic urticarial vasculitis syndrome: a report of three paediatric cases. *Rheumatology*, **2014**, 53, 1409-13	3.9	12
114	High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. *Clinical and Experimental Immunology*, **2003**, 131, 355-63	6.2	12
113	The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. *PLoS ONE*, **2019**, 14, e0226043	3.7	12
112	Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever. *Annals of the Rheumatic Diseases*, **2020**, 79, 960-968	2.4	12
111	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. *Arthritis and Rheumatology*, **2014**, 66, S83-S84	9.5	11
110	Tocilizumab for systemic juvenile idiopathic arthritis. *New England Journal of Medicine*, **2013**, 368, 1256-7	59.2	11
109	Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. *Rheumatology*, **1999**, 38, 773	3.9	11
108	Interleukin-18 in pediatric rheumatic diseases. *Current Opinion in Rheumatology*, **2019**, 31, 421-427	5.3	11
107	Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication. *Journal of Rheumatology*, **2018**, 45, 956-961	4.1	10
106	NLRP2 Regulates Proinflammatory and Antiapoptotic Responses in Proximal Tubular Epithelial Cells. *Frontiers in Cell and Developmental Biology*, **2019**, 7, 252	5.7	10
105	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. *Journal of Rheumatology*, **2019**, 46, 1117-1126	4.1	9
104	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. *Arthritis Research and Therapy*, **2020**, 22, 71	5.7	9

103	Lack of temporal association of iridocyclitis with IgG reactivities to core histones and nucleosome subparticles in pauciarticular juvenile chronic arthritis. *Rheumatology*, **1995**, 34, 507-11	3.9	9
102	Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. *Rheumatology*, **2018**, 57, 1752-1760	3.9	9
101	Different responses of PC12 cells to different pro-nerve growth factor protein variants. *Neurochemistry International*, **2019**, 129, 104498	4.4	8
100	An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. *Osteoporosis International*, **2014**, 25, 681-92	5.3	8
99	Anti interferon-gamma (IFN) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. *Pediatric Rheumatology*, **2015**, 13,	3.5	8
98	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. *Acta Paediatrica, International Journal of Paediatrics*, **2007**, 91, 246-247	3.1	8
97	CD5-positive B cells in type 1 (insulin-dependent) diabetic children. *Diabetes Research and Clinical Practice*, **1993**, 19, 17-22	7.4	8
96	Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic´Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2021**, 73, 1053-1061	9.5	8
95	Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. *Arthritis and Rheumatology*, **2021**, 73, 530-541	9.5	8
94	Caspase-1 levels in biological fluids from patients with multiple sclerosis and from patients with other neurological and non-neurological diseases. *European Cytokine Network*, **2002**, 13, 99-103	3.3	8
93	Decreased fibrinolytic activity in juvenile chronic arthritis. *Annals of the Rheumatic Diseases*, **1990**, 49, 973-5	2.4	7
92	Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. *Frontiers in Pediatrics*, **2020**, 8, 576912	3.4	7
91	Increased expression of alpha(1,3)-fucosyltransferase-VII and P-selectin binding of synovial fluid T cells in juvenile idiopathic arthritis. *Journal of Rheumatology*, **2003**, 30, 1611-5	4.1	7
90	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. *Frontiers in Pharmacology*, **2018**, 9, 1526	5.6	6
89	A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study. *Arthritis and Rheumatology*, **2014**, 66, S8-S9	9.5	6
88	Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model. *Pediatric Rheumatology*, **2014**, 12,	3.5	6
87	FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial. *Annals of the Rheumatic Diseases*, **2013**, 71, 425.1-425	2.4	6
86	Industrial Synthesis of 4-Chloro,11-arylestradiol: How to Circumvent a Poor Diastereoselectivity. *Organic Process Research and Development*, **2004**, 8, 219-228	3.9	6

85	Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis. *Frontiers in Genetics*, **2020**, 11, 937	4.5	6
84	Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?. *Pediatric Rheumatology*, **2019**, 17, 84	3.5	6
83	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. *Journal of Rheumatology*, **2018**, 45, 1173-1179	4.1	6
82	An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. *Pediatric Rheumatology*, **2019**, 17, 25	3.5	5
81	A patient with stimulator of interferon genes-associated vasculopathy with onset in infancy without skin vasculopathy. *Rheumatology*, **2020**, 59, 905-907	3.9	5
80	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2019**, 71, 1976-1984	9.5	5
79	Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. *Pediatric Rheumatology*, **2014**, 12, P56	3.5	5
78	Targeting interferon-□n hyperinflammation: opportunities and challenges. *Nature Reviews Rheumatology*, **2021**, 17, 678-691	8.1	5
77	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. *Rheumatology*, **2021**, 60, 3799-3808	3.9	5
76	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. *Rheumatology*, **2021**, 60, 4568-4580	3.9	5
75	Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis. *Journal of the Pediatric Infectious Diseases Society*, **2016**, 5, 76-9	4.8	4
74	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. *Arthritis and Rheumatology*, **2014**, 66, S5-S6	9.5	4
73	The macrophage migration inhibitory factor -173G/C polymorphism is not significantly associated with necrotizing enterocolitis in preterm infants. *Journal of Pediatric Surgery*, **2013**, 48, 1499-502	2.6	4
72	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. *Arthritis and Rheumatology*, **2014**, 66, S17-S18	9.5	4
71	A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. *Arthritis and Rheumatology*, **2014**, 66, S80-S81	9.5	4
70	Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. *Pediatric Rheumatology*, **2014**, 12,	3.5	4
69	Mechanisms inducing low bone density in Duchenne Muscular Dystrophy. *Bone*, **2009**, 44, S237-S238	4.7	4
68	OP0290 EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). *Annals of the Rheumatic Diseases*, **2020**, 79, 180.1-180	2.4	4

67	The activating p.Ser466Arg change in STAT1 causes a peculiar phenotype with features of interferonopathies. *Clinical Genetics*, **2019**, 96, 585-589	4	3
66	The phenotypic variability of PAPA syndrome: evidence from the Eurofever Registry. *Pediatric Rheumatology*, **2015**, 13,	3.5	3
65	High levels of interferon-gamma (IFN) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFN production in MAS. *Pediatric Rheumatology*, **2015**, 13,	3.5	3
64	A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2014**, 66, S67-S68	9.5	3
63	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2014**, 66, S23-S24	9.5	3
62	Anti-DNA antibodies in the primary antiphospholipid syndrome. *Rheumatology*, **1993**, 32, 1028	3.9	3
61	Effects of Retinoic Acid on TGF Receptor Expression in HL-60 Cells. *Annals of the New York Academy of Sciences*, **1990**, 593, 310-312	6.5	3
60	Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma. *Frontiers in Immunology*, **2021**, 12, 663329	8.4	3
59	FRI0488 A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). *Annals of the Rheumatic Diseases*, **2016**, 75, 615.2-616	2.4	3
58	Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study. *Lancet Rheumatology, The*, **2021**, 3, e563-e573	14.2	3
57	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study. *Biologics: Targets and Therapy*, **2020**, 14, 13-21	4.4	2
56	THU0509 Improvement of disease activity in patients with colchicine-resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial **2017**,		2
55	Neutralization of Interferon-gamma is efficacious in a mouse model of HLH secondary to chronic inflammation. *Pediatric Rheumatology*, **2015**, 13,	3.5	2
54	S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH. *Pediatric Rheumatology*, **2015**, 13,	3.5	2
53	Chronic recurrent multifocal osteomyelitis (CRMO): typical patterns of bone involvement on MRI with particular emphasis on Whole Body MRI (WBMRI). *Pediatric Rheumatology*, **2015**, 13,	3.5	2
52	Whole-Body MRI versus bone scintigraphy: which is the best diagnostic tool in patients with chronic recurrent multifocal osteomyelitis (CRMO)?. *Pediatric Rheumatology*, **2015**, 13,	3.5	2
51	Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. *Annals of the Rheumatic Diseases*, **1989**, 48, 582-5	2.4	2
50	Morphology of the gastric mucosa, gastric secretion and serum gastrin concentration following a test meal. *Digestion*, **1978**, 17, 18-28	3.6	2

49	Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition. *Blood*, **1991**, 77, 1248-1255	2.2	2
48	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. *Arthritis Research and Therapy*, **2020**, 22, 211	5.7	2
47	FRI0489 Canakinumab Improves Patient Reported Outcomes in Patients with Periodic Fever Syndromes. *Annals of the Rheumatic Diseases*, **2016**, 75, 616.1-616	2.4	2
46	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. *Clinical and Experimental Rheumatology*, **2019**, 37, 1084-1091	2.2	2
45	Acute rheumatic fever prophylaxis in high-income countries: clinical observations from an Italian multicentre, retrospective study. *Clinical and Experimental Rheumatology*, **2020**, 38, 1016-1020	2.2	2
44	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. *Acta Paediatrica, International Journal of Paediatrics*, **2002**, 91, 246-7	3.1	2
43	Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients. *Microorganisms*, **2020**, 8,	4.9	1
42	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). *Rheumatology International*, **2018**, 38, 251-258	3.6	1
41	THU0569 Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS). *Annals of the Rheumatic Diseases*, **2016**, 75, 397.3-398	2.4	1
40	OP0062 The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Serious Adverse Events. The 5882 Pharmachild Cohort. *Annals of the Rheumatic Diseases*, **2015**, 74, 91-91	2.4	1
39	Repositioning agricultural development in Africa through appropriate technology transfer. *African Journal of Science, Technology, Innovation and Development*, **2014**, 6, 45-50	0.7	1
38	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. *Arthritis and Rheumatology*, **2014**, 66, S96-S97	9.5	1
37	Reciprocal interactions between the GH/IGF-I system and cytokines. *NeuroImmune Biology*, **2002**, 27-35		1
36	Secondary thrombocytosis. *Archives of Disease in Childhood*, **1993**, 69, 170-1	2.2	1
35	Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the Pharmachild registry.. *Journal of Rheumatology*, **2022**,	4.1	1
34	Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts. *Frontiers in Immunology*, **2021**, 12, 656407	8.4	1
33	IgM on the surface of T cells: a novel biomarker of pediatric-onset systemic lupus erythematosus. *Pediatric Nephrology*, **2021**, 36, 909-916	3.2	1
32	Macrophage Activation Syndrome in Rheumatic Diseases (MAS-HLH) **2018**, 233-246		1

31	Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis. *Pediatric Rheumatology*, **2021**, 19, 123	3.5	1
30	CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REAL-LIFE DATA FROM A RETROSPECTIVE ITALIAN COHORT. *Rheumatology*, **2021**,	3.9	1
29	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFN) Monoclonal Antibody. *Blood*, **2021**, 138, 2058-2058	2.2	0
28	Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFN) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases. *Blood*, **2021**, 138, 4195-4195	2.2	0
27	AB1059 A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILL S DISEASE. *Annals of the Rheumatic Diseases*, **2020**, 79, 1819.2-1820	2.4	0
26	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. *Arthritis Care and Research*, **2021**, 73, 1264-1274	4.7	0
25	Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in Critically Ill Children. *Blood Purification*, **2021**, 1-8	3.1	0
24	Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. *Pediatric Rheumatology*, **2021**, 19, 144	3.5	0
23	Pro Nerve Growth Factor and Its Receptor p75NTR Activate Inflammatory Responses in Synovial Fibroblasts: A Novel Targetable Mechanism in Arthritis.. *Frontiers in Immunology*, **2022**, 13, 818630	8.4	0
22	Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases **2019**, 751-774		
21	OP0217 Adjudication of Infections in The Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated with Biologic Agents and/or Methotrexate. *Annals of the Rheumatic Diseases*, **2016**, 75, 139.1-139	2.4	
20	Kikuchi-Fujimoto disease in patient with systemic phacomatosis pigmentovascularis. *Blood Coagulation and Fibrinolysis*, **2014**, 25, 783-5	1	
19	Acute rheumatic fever with chorea. *Archives of Disease in Childhood*, **2013**, 98, 203	2.2	
18	THU0508 Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 5-Year Data from Tender, A Phase 3 Clinical Trial. *Annals of the Rheumatic Diseases*, **2015**, 74, 384.1-384	2.4	
17	SAT0483 Tapering and Withdrawal of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results from an Alternative Dosing Regimen in the Tender Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 835.1-835	2.4	
16	FRI0323 Cronic Non-Bacterial Osteomyelitis (CNO) in a Cohort of Pediatric Patients: Clinical, Biological and Radiological Response to Treatment with Anakinra. *Annals of the Rheumatic Diseases*, **2015**, 74, 541.2-541	2.4	
15	OP0134 Increased Muscle Interferon- Expression Levels in Juvenile Dermatomyositis. *Annals of the Rheumatic Diseases*, **2015**, 74, 119.1-119	2.4	
14	OP0008 Single Center Experience in Next Generation Sequencing for Genetic Diagnosis of Autoinflammatory Disorders (AIDS). *Annals of the Rheumatic Diseases*, **2015**, 74, 67.1-67	2.4	

List of Publications

13	PP11. Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year data from tender. *Rheumatology*, **2015**, 54, ii9-ii9	3.9
12	SAT0325 Chronic Recurrent Multifocal Osteomyelitis (CRMO): Typical Patterns of Bone Involvement on MRI with Particular Emphasis on Whole Body MRI (WBMRI). *Annals of the Rheumatic Diseases*, **2015**, 74, 776.2-776	2.4
11	A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. *Arthritis and Rheumatology*, **2014**, 66, S222-S223	9.5
10	OP0175 The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years. *Annals of the Rheumatic Diseases*, **2013**, 71, 114.1-114	2.4
9	203 Low Mannose Binding Lectin (MBL) Serum Levels And Hospital Acquired Infections (HAI) in Neonates in a Neonatal Intensive Care Unit (NICU). *Pediatric Research*, **2004**, 56, 498-498	3.2
8	Juvenile idiopathic arthritis: will etanercept be an improvement over current therapies?. *BioDrugs*, **2000**, 14, 93-8	7.9
7	Synergy between Transforming Growth Factor-□and Tumor Necrosis Factor-□in the Induction of Monocytic Differentiation of Human Leukemic Cell Linesa. *Annals of the New York Academy of Sciences*, **1990**, 593, 334-337	6.5
6	Impact of chronic inflammation on bone during childhood. *Future Rheumatology*, **2006**, 1, 455-464	
5	Anti-interferon-□Therapy for Cytokine Storm Syndromes **2019**, 569-580	
4	OP0272 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL. *Annals of the Rheumatic Diseases*, **2020**, 79, 169.2-170	2.4
3	Response to: Correspondence on Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial by Satis. *Annals of the Rheumatic Diseases*, **2020**,	2.4
2	Reumatologia. *Medico E Bambino*, **2021**, 40, 1-3	0.4
1	A rare cause of multiple airways narrowing in a 15-year-old girl. *Thorax*, **2021**, 76, 205-207	7.3